Research summary
The study tests a FOLR1-anchored, DR5-activating bispecific antibody in ovarian cancer models.
Study context
FOLR1-anchored DR5 bispecific antibody
Can tumor-antigen anchoring help concentrate death-receptor activation where FOLR1 is expressed?
How it was studied
The authors engineered and compared dual-specificity antibody formats, measured target binding and death signaling, and studied ovarian tumor models. The paper includes cell-based experiments and in vivo preclinical work; it does not describe an approved human therapy.
Selected findings
- The article describes antibody architecture combining FOLR1 and DR5 specificity.
- The reported experiments test FOLR1-dependent localization of DR5 agonism in ovarian cancer systems.
Proof of concept in laboratory and animal-model settings. The antibody is not represented here as an approved treatment. The U.S. grant and earlier application are members of one family, not separate inventions.
Read the full project analysis → · View figures in the original paper →
Authors
Cite this work
Gururaj Shivange, Karol Urbanek, Piotr Przanowski, Justin S A Perry, James Jones, Robert Haggart, Christina Kostka, Tejal Patki, Edward Stelow, Yuliya Petrova, Danielle Llaneza, Marty Mayo, Kodi S Ravichandran, Charles N Landen, Sanchita Bhatnagar, Jogender Tushir-Singh (2018). A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer. Cancer cell, 331-345.e11. https://doi.org/10.1016/j.ccell.2018.07.005